Search Videos and More
Video
Blood Cancer Research: Clinical Trial Helps Younger Patient
A patient shares her journey getting diagnosed with chronic lymphocytic leukemia in her 30's. Dana-Farber Cancer Institute's Matthew Davids, MD, MMSc, enrolled her on a clinical trial and details the results of that study. The research is now getting presented at ASH21.
Video
Inadequate SARS-COV-2 Vaccine Effectiveness in Patients with Multiple Myeloma: A Large Nationwide Veterans Affairs Study
Dana-Farber Cancer Institute's Nikhil C. Munshi, MD, details study looking at COVID-19 vaccine effectiveness in patients with multiple myeloma. Research presented at ASH21.
News
ASH 2021 Highlights - CME
Register for 2021 ASH Highlights CME
Video
New Study Reveals Elevated Rates of Blood Cancer Precursor Condition in Groups at High Risk for Multiple Myeloma
Dana-Farber Cancer Institute research shows elevated rates of a blood cancer precursor condition in groups at high risk for multiple myeloma.
News
Study of Fully Vaccinated Patients with Cancer who had Breakthrough COVID-19 Shows 13% Mortality Rate
The first study to evaluate the clinical characteristics and outcomes of fully vaccinated patients with cancer who had breakthrough COVID-19 infections indicates they remained at high risk for hospitalization and death.
Video
COVID-19 and Cancer: Breakthrough Infections
New study: Fully vaccinated patients with cancer who had breakthrough COVID-19 infections remained at high risk for hospitalization and death. Dana-Farber's Toni Choueiri, MD, highlights the research.
Video
Blood Cancer Research: Clinical trial helps younger patient
Dr. Matthew Davids presented a study that demonstrated the ibrutinib+FCR drug combination keeps chronic lymphocytic leukemia in young patients in remission for several years.
Video
COVID-19 vaccine and blood cancer
Dr. Nikhil Munshi and colleagues reported a study demonstrating that COVID-19 vaccination offers less protection for multiple myeloma patients, reinforcing the need for these patients to use additional precautions.
Video
Blood Cancer: Higher rates of precursor in high-risk individuals
Dr. Irene Ghobrial and Dr. Habib El-Khoury shared the first results from the Promise study, which screens individuals at high risk for multiple myeloma.
News
FDA Approval Offers Hope For Prevention of Acute Graft-Versus-Host Disease
Based on a clinical trial led by Leslie S. Kean, MD, PhD, of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, the FDA has approved abatacept for the prevention of GVHD. This approval will allow many more patients to safely and effectively undergo stem cell transplants, particularly patients of diverse ethnicities who have more difficulty finding appropriately matched donors.
News
Drug Combination Found to Keep Chronic Lymphocytic Leukemia in Young Patients in Remission for Several Years
A new study by Dana-Farber Cancer Institute researchers suggests that a 2.5-year regimen involving ibrutinib and chemoimmunotherapy can provide deep, and lasting remissions for patients with chronic lymphocytic leukemia (CLL).
News
Molecular Analysis Advances Risk Profiling and Assessment of Immunotherapy Response in Smoldering Myeloma
Molecular and genetic research by scientists at Dana-Farber Cancer Institute has advanced the categorization of different risk groups in patients with smoldering myeloma, a premalignant condition that can – but doesn’t always – progress to the blood cancer, multiple myeloma.